No Data
No Data
Codexis to Sell Pompe, Fabry Assets to Crosswalk Therapeutics
6-K: Report of foreign private issuer (related to financial reporting)
20-F: Registration statement / Annual report / Transition report
6-K: Notice of Resolutions at the 148th Ordinary General Meeting of Shareholders
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2023
OSAKA, Japan, June 26, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2024 (the "Annual Report") with the U.S. S
Wave Jumps on Trial Data for Huntington's Disease Therapy